imidocarb-dipropionate and Chronic-Disease

The objective of this study was to evaluate the safety and efficacy of imidocarb dipropionate administered to cats for clearing chronic Haemobartonella felis infections. Imidocarb dipropionate was administered twice at 5.0 mg/kg by intramuscular injection 14 days apart to eight cats with chronic, subclinical haemobartonellosis. Clinical signs and laboratory parameters were monitored throughout the study. Polymerase chain reaction (PCR) for the detection of Mycoplasma haemofelis (large form of H. felis) and Mycoplasma haemominutum (small form of H. felis) was performed to assess for parasitologic cure. Four of the eight cats treated with imidocarb dipropionate became transiently PCR-negative after treatment; untreated control cats (n = 2) were persistently PCR-positive. Two persistently PCR-negative cats were given one dose of methylprednisolone acetate; one was PCR-positive 10 days later. There was no evidence of significant toxicity associated with this imidocarb treatment protocol.

Topics: Anaplasmataceae Infections; Animals; Anti-Bacterial Agents; Cat Diseases; Cats; Chronic Disease; Female; Imidocarb; Male

The hydroxynaphthoquinone, atovaquone (Wellvone, Glaxo-Wellcome Ltd.) was found to have significant activity against Babesia microti, the main cause of human babesiosis in the U.S.A. This activity compares well with that of the most effective babesicide currently available for use in animals, imidocarb dipropionate, that unlike atovaquone is not licensed for use in humans. Treatment with well tolerated doses of atovaquone results in a rapid reduction in parasitemias and an early disappearance of parasites from blood smears. However, in common with all the other babesicides tested, atovaquone did not sterilize gerbils of infection, even at very high daily doses administered for up to 10 days. A combination of atovaquone and clindamycin was more effective than atovaquone alone in the treatment of both acute and chronic infections but failed to eliminate parasites completely.

Topics: Acute Disease; Animals; Antiprotozoal Agents; Atovaquone; Babesiosis; Chronic Disease; Clindamycin; Diminazene; Dose-Response Relationship, Drug; Drug Resistance; Drug Therapy, Combination; Gerbillinae; Humans; Imidocarb; Naphthoquinones; Pentamidine; Recurrence